Doc Curtis chimes in on drug companies

Dear Editor,

I did appreciate the comments by Peter J. Pitts, President, Center for Medicine, in the October 14th issue of the PCN. It did help clarify some of the incredible obstacles, issues and expenses the drug companies are compelled to deal with in the research and development (R & D) of new and /or modified pharmaceutical and vaccine production. His points were valid, accurate and well stated. And while I have been turned out to pasture for a few years now there are a few other issues which are not as clear cut as those Mr. Pitts addressed but which can certainly impact the cost...